Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Alkem Labs

Pharmaceutical intelligence for Alkem Labs with 13 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 9
Catalysts: 4
Assets: 7

Recent signals(9)

RegulatoryAugust 5, 2026

FDA Accepts Supplement for Rosuvastatin Calcium by Alkem Labs

The FDA has accepted a supplemental application for Rosuvastatin Calcium from Alkem Labs.

StrategyAugust 5, 2026

FDA Grants Approval for Tacrolimus ANDA203740 by Alkem Labs

The FDA has granted approval for the ANDA203740 application for Tacrolimus submitted by Alkem Labs.

RegulatoryJuly 29, 2026

FDA Accepts Supplement Application for Olmesartan Medoxomil and Hydrochlorothiazide

The FDA has accepted a supplemental application for the combination of Olmesartan Medoxomil and Hydrochlorothiazide submitted by Alkem Labs.

RegulatoryJuly 28, 2026

FDA Approval Process Update for Tolvaptan by Alkem Labs

The FDA has received an application (ANDA220147) for Tolvaptan from Alkem Labs, currently under standard review.

RegulatoryJuly 24, 2026

FDA Accepts Supplement Application for Ibuprofen and Famotidine by Alkem Labs

The FDA has accepted a supplemental application for a combination product of ibuprofen and famotidine submitted by Alkem Labs.

StrategyJuly 5, 2026

FDA Grants AP Status for Olmesartan Medoxomil and Hydrochlorothiazide ANDA207037

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Olmesartan Medoxomil and Hydrochlorothiazide submitted by Alkem Labs.

StrategyJuly 5, 2026

FDA Accepts ANDA for Tolvaptan by Alkem Labs

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Tolvaptan submitted by Alkem Labs.

RegulatoryJune 25, 2026

FDA Approves Supplement for Morphine Sulfate by Alkem Labs

The FDA has approved a supplemental application for Morphine Sulfate submitted by Alkem Labs.

StrategyJune 23, 2026

FDA Approves Solriamfetol Hydrochloride by Alkem Labs

The FDA has approved Solriamfetol Hydrochloride under application ANDA218722 submitted by Alkem Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(5)

RegulatoryAugust 5, 2026

FDA Accepts Supplement for Rosuvastatin Calcium by Alkem Labs

The FDA has accepted a supplemental application for Rosuvastatin Calcium from Alkem Labs.

RegulatoryJuly 29, 2026

FDA Accepts Supplement Application for Olmesartan Medoxomil and Hydrochlorothiazide

The FDA has accepted a supplemental application for the combination of Olmesartan Medoxomil and Hydrochlorothiazide submitted by Alkem Labs.

RegulatoryJuly 28, 2026

FDA Approval Process Update for Tolvaptan by Alkem Labs

The FDA has received an application (ANDA220147) for Tolvaptan from Alkem Labs, currently under standard review.

RegulatoryJuly 24, 2026

FDA Accepts Supplement Application for Ibuprofen and Famotidine by Alkem Labs

The FDA has accepted a supplemental application for a combination product of ibuprofen and famotidine submitted by Alkem Labs.

RegulatoryJune 25, 2026

FDA Approves Supplement for Morphine Sulfate by Alkem Labs

The FDA has approved a supplemental application for Morphine Sulfate submitted by Alkem Labs.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Hydrochlorothiazide →

Morphine Sulfate →

Solriamfetol Hydrochloride →

Therapeutic areas

Antihypertensive →

Cardiovascular →

Cardiovascular · Antihypertensive →

Combination Therapy →

Hypertension →

Nephrology · Vasopressin Antagonist →

Neurology · Wakefulness-promoting agent →

Pain Management →

Pain Management · Opioid →

Transplantation →

Vasopressin Antagonist →

Wakefulness-promoting agent →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.